.svg){kind=small}
Market Insights Snapshot
In June 2026, Amend Cannabis concentrated 69.93% of sales in Topical while Tincture & Sublingual comprised 30.07%, a mix that shifted as Topical fell 20.17% month over month and Tincture & Sublingual rose 68.39% month over month; year over year, Topical expanded 1007.50% and the brand-level average price declined 5.57%. With average prices at $44.77 overall and Topical priced higher at 46.84 versus 40.59 for Tincture & Sublingual, the mix tilt combined with divergent MoM trajectories implies the brand is trading volume toward lower-priced formats while still anchored in a single lead category.
The 1483.73% year-over-year brand sales gain alongside a 77.88% decline over 24 months indicates a rebound phase concentrated in Missouri around Topical, but the 20.17% MoM contraction in that lead category against a 68.39% MoM surge in Tincture & Sublingual suggests near-term resilience depends on diversifying away from a single-category reliance. Given no reported Topical rank in Missouri and a 30.07% share now sitting in Tincture & Sublingual, the pattern implies the brand’s positioning is shifting from a Topical-led niche toward a two-category footprint that can absorb price compression and stabilize growth.
Competitive Landscape
Amend Cannabis sits at rank #7 in Missouri Topical in June 2026, an improvement of 4 positions from #11 year over year, and a 4-rank climb from March 2026’s #11 to June 2026’s #7 signals mid-year momentum; meanwhile, Mary's Medicinals held #1 with a -2.9% year-over-year sales change while Escape Artists stayed at #2 despite a -41.8% decline, indicating that Amend Cannabis’s upward movement is occurring amid mixed top-tier contraction. With Heartland Labs stable at #3 on +10.4% sales and Drool advancing from #5 to #4 on +14.0%, the competitive middle is tightening as Vlasic Labs rose from #6 to #5 on +16.7%, placing pressure on the #7 spot; against that backdrop, Amend Cannabis’s recovery from its July 2024 peak at #3 toward today’s #7 suggests a rebound path is open but will likely require share gains against faster-growing neighbors rather than reliance on top-two softness.
Notable Products
CBD/THC 1:1 Amend Tincture (400mg CBD, 400mg THC) posted the sharpest movement in June 2026 with a +191% month-over-month surge into rank 3, while CBD/THC 1:1 Amend Infused Balm (500mg CBD, 500mg THC) fell -64% to rank 5, indicating volatility at the extremes of potency. The category mix tightened as two Tincture & Sublingual SKUs sat at ranks 2 and 3 with +50% and +191% MoM respectively, against the flagship CBD/THC 1:1 Amend Infused Balm (250mg CBD, 250mg THC) slipping -18% yet holding rank 1, and this tilt implies incremental share is migrating from legacy topicals toward faster-replenish tinctures. Four of the top five products are split between Topical and Tincture & Sublingual with three Topicals still present but two posting negative or modest growth, pointing to a portfolio where tinctures are now the growth engine while topicals anchor baseline revenue at $8,827.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
